Kimia Farma Persero Tbk (KAEF) - Total Assets
Based on the latest financial reports, Kimia Farma Persero Tbk (KAEF) holds total assets worth Rp14.97 Trillion IDR (≈ $877.37 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Kimia Farma Persero Tbk shareholders equity for net asset value and shareholders' equity analysis.
Kimia Farma Persero Tbk - Total Assets Trend (2002–2024)
This chart illustrates how Kimia Farma Persero Tbk's total assets have evolved over time, based on quarterly financial data.
Kimia Farma Persero Tbk - Asset Composition Analysis
Current Asset Composition (December 2024)
Kimia Farma Persero Tbk's total assets of Rp14.97 Trillion consist of 26.3% current assets and 73.7% non-current assets.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp40.37 Billion | 2.9% |
| Accounts Receivable | Rp1.35 Trillion | 9.0% |
| Inventory | Rp1.50 Trillion | 10.1% |
| Property, Plant & Equipment | Rp9.56 Trillion | 63.9% |
| Intangible Assets | Rp57.03 Billion | 0.4% |
| Goodwill | Rp53.68 Billion | 0.4% |
Asset Composition Trend (2002–2024)
This chart illustrates how Kimia Farma Persero Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KAEF market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kimia Farma Persero Tbk's current assets represent 26.3% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 2.9% of total assets in 2024, down from 11.6% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is property, plant & equipment at 63.9% of total assets.
Kimia Farma Persero Tbk Competitors by Total Assets
Key competitors of Kimia Farma Persero Tbk based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$7.84 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
|
Cyclopharm Ltd
AU:CYC
|
Australia | AU$55.91 Million |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
|
Brazil | R$5.64 Billion |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
|
China | CN¥233.15 Billion |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
|
China | CN¥83.17 Billion |
Kimia Farma Persero Tbk - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.59 | 0.61 | 0.89 |
| Quick Ratio | 0.39 | 0.37 | 0.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rp-2.80 Trillion | Rp-3.52 Trillion | Rp-810.75 Billion |
Kimia Farma Persero Tbk - Advanced Valuation Insights
This section examines the relationship between Kimia Farma Persero Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.50 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -14.9% |
| Total Assets | Rp14.97 Trillion |
| Market Capitalization | $155.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kimia Farma Persero Tbk's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kimia Farma Persero Tbk's assets decreased by 14.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kimia Farma Persero Tbk (2002–2024)
The table below shows the annual total assets of Kimia Farma Persero Tbk from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Rp14.97 Trillion ≈ $877.01 Million |
-14.89% |
| 2023-12-31 | Rp17.59 Trillion ≈ $1.03 Billion |
-13.60% |
| 2022-12-31 | Rp20.35 Trillion ≈ $1.19 Billion |
+14.60% |
| 2021-12-31 | Rp17.76 Trillion ≈ $1.04 Billion |
+1.12% |
| 2020-12-31 | Rp17.56 Trillion ≈ $1.03 Billion |
-4.30% |
| 2019-12-31 | Rp18.35 Trillion ≈ $1.08 Billion |
+94.00% |
| 2018-12-31 | Rp9.46 Trillion ≈ $554.34 Million |
+55.19% |
| 2017-12-31 | Rp6.10 Trillion ≈ $357.21 Million |
+32.16% |
| 2016-12-31 | Rp4.61 Trillion ≈ $270.28 Million |
+42.53% |
| 2015-12-31 | Rp3.24 Trillion ≈ $189.63 Million |
+9.03% |
| 2014-12-31 | Rp2.97 Trillion ≈ $173.92 Million |
+20.08% |
| 2013-12-31 | Rp2.47 Trillion ≈ $144.85 Million |
+19.05% |
| 2012-12-31 | Rp2.08 Trillion ≈ $121.67 Million |
+15.72% |
| 2011-12-31 | Rp1.79 Trillion ≈ $105.14 Million |
+8.26% |
| 2010-12-31 | Rp1.66 Trillion ≈ $97.11 Million |
+6.06% |
| 2009-12-31 | Rp1.56 Trillion ≈ $91.56 Million |
+8.09% |
| 2008-12-31 | Rp1.45 Trillion ≈ $84.71 Million |
+4.25% |
| 2007-12-31 | Rp1.39 Trillion ≈ $81.26 Million |
+9.95% |
| 2006-12-31 | Rp1.26 Trillion ≈ $73.90 Million |
+7.10% |
| 2005-12-31 | Rp1.18 Trillion ≈ $69.00 Million |
+0.35% |
| 2004-12-31 | Rp1.17 Trillion ≈ $68.76 Million |
-14.14% |
| 2003-12-31 | Rp1.37 Trillion ≈ $80.09 Million |
+31.60% |
| 2002-12-31 | Rp1.04 Trillion ≈ $60.85 Million |
-- |
About Kimia Farma Persero Tbk
PT Kimia Farma Tbk engages in the research, development, manufacture, and sale of pharmaceutical products in Indonesia and internationally. It offers generic drugs and ethical products; over-the-counter products and herbs; and cosmetic products. The company also provides integrated health clinic and medical laboratory services; operates a beauty clinic; and retails pharmaceutical products, as wel… Read more